The CenterWatch Weekly, June 26, 2017
QuintilesIMS to buy DrugDev
QuintilesIMS has reportedly reached an agreement to buy DrugDev, a technology company that has built one of the industry’s largest global investigator networks and data sharing platforms, the latest in series of significant mergers among CROs during recent months.
Parexel developments offer a clinical trial, big data parable for the times
Drug clinical trials are on the same disruptive fast track, as evidenced by a trio of announcements from Parexel. The biopharmaceutical CRO timed the key announcements around the annual Drug Information Association meeting (DIA) held last week in Chicago. Two of the announcements—a new Big Data product launch and a collaboration to capture patient information in clinical trials—are newsworthy. But the third announcement—that Parexel has entered into an agreement to be acquired for $5 billion by Pamplona, a private equity firm—is an indication of the growing pace of mergers in the sector powered by the demand for data assets.
To read the full articles for this issue of The CenterWatch Weekly, please click here for subscription information.